TherMatrx TMx-2000 PMA Backed By Impressive Pivotal Trial Results
This article was originally published in The Gray Sheet
Executive Summary
TherMatrx' modular premarket approval application for the TMx-2000 microwave thermotherapy to treat benign prostatic hyperplasia is on track for approval by late 2000 or early 2001, following submission of the first module in April.
You may also be interested in...
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.